PATENT CLAIM ANALYSIS

Application Number: 16170134
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Claim (Index 8):
The method of  claim 4 , wherein\n the pharmaceutical composition comprises 5 mg linagliptin and 1000 mg metformin in extended release form, and optionally one or more pharmaceutically auxiliaries, or wherein the pharmaceutical composition comprises 2.5 mg linagliptin and 750 mg or 1000 mg metformin in extended release form, and optionally one or more pharmaceutically auxiliaries.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '15918401', '15354053', '14918727', '14928048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7235019562548491
- 35 USC 102 Novelty (BERT): 0.5971464219873989
- Combined Prediction Score: 0.7108664028281041
- Mean Citation Score: 371.19762
- Max Citation Score: 489.67908
- Similarity Product: 469.2407215066624

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test